Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 354

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1C
Chunk 354
---
13,817 
  
    INKmune (High Risk MDS/AML & Prostate Cancer) and CORDStrom 
     4,589  
     3,296 
  
    Preclinical and other programs 
     611  
     921 
  
    Accrued research and development rebate 
     (1,823) 
     (3,040)
  
    Total external costs 
     27,142  
     14,994 
  
    Internal Costs 
     6,024  
     5,279 

    $33,166  
    $20,273 

We
typically use our employee resources across our development programs. We track outsourced development costs by product candidate or development
program, but we do not allocate internal costs personnel costs including salaries and stock-based compensation to specific product candidates
or development programs.

We
participate, through our wholly owned subsidiary in Australia, in the Australian research and development tax incentive program, such
that a percentage of our qualifying research and development expenditures are reimbursed by the Australian government, and such incentives
are reflected as a reduction of research and development expense. The Australian research and development tax incentive is recognized
when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and the amount of the
consideration can be reliably measured.

60

Substantially all of our research
and development expenses to date have been incurred in connection with our current and future product candidates. We expect our research
and development expenses to increase significantly for the foreseeable future as we advance an increased number of our product candidates
through clinical development, including the conduct of our planned clinical trials and manufacturing drug to be used in those clinical
trials. The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. The successful
development of product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs required
to complete the remaining development of any product candidates. This is due to the numerous risks and uncertainties associated with the
development of product candidates.

The costs of clinical trials
may vary significantly over the life of a project owing to, but not limited to, the following:

    ●
    per patient trial costs;

    ●
    the number of sites included in the clinical trials;

    ●
    the countries in which the clinical trials are conducted;

    ●
    the length of time required to enroll eligible patients